Flavolife 02

Flavolife 02 is a preclinical-stage small molecule pan-senolytic being developed by Flavolife for the treatment of colorectal cancer (CRC). It is part of a platform of compounds based on a proprietary flavonoid scaffold designed to selectively eliminate senescent cells. Senescent cells are non-dividing cells that accumulate in tissues and the tumor microenvironment in response to stress or aging, where they can promote inflammation, tumor progression, and resistance to standard therapies. By clearing these cells, Flavolife 02 aims to disrupt the pro-tumorigenic environment and inhibit cancer growth. While the specific molecular targets (e.g., specific receptors or enzymes) of the flavonoid scaffold have not been disclosed by the developer, the compound is intended to function as a broad-spectrum senolytic agent.